SURGICAL SCIENCE SWEDEN
Research SURGICAL SCIENCE SWEDEN (4P41) on Bullrun: valuation model: 33.5% overvalued, market cap EUR 144.71M, P/E 31.5. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker4P41
- ExchangeF
- CountrySweden
- SectorHealthcare
- IndustryHealth Information Services
- CurrencyEUR
- Valuation signal33.5% overvalued
- Market capEUR 144.71M
- P/E31.5
- Financial periodQ4 2025
- RevenueEUR 268.85M
- Net incomeEUR 33.26M
- Free cash flowEUR 57.76M
- Gross margin66.3%
Valuation Snapshot
Bullrun's latest valuation model marks SURGICAL SCIENCE SWEDEN as 33.5% overvalued; latest market cap is EUR 144.71M; P/E is 31.5.
About SURGICAL SCIENCE SWEDEN
Surgical Science Sweden AB (publ) develops and markets virtual reality simulators and customized training solutions for evidence-based medical training in Europe, North and South America, Asia, and internationally. The company offers Angio Mentor simulator for endovascular training; BRONCH Express, a portable version of BRONCH mentor simulator; ARTHRO Mentor for arthroscopic surgery skills acquisition; BRONCH Mentor, a simulator for optimizing bronchoscopy training; GI Mentor, a simulator for GI Endoscopy;
Frequently asked questions
Is SURGICAL SCIENCE SWEDEN overvalued or undervalued?
Bullrun's valuation model currently marks SURGICAL SCIENCE SWEDEN as 33.5% overvalued.
What is SURGICAL SCIENCE SWEDEN's market cap?
SURGICAL SCIENCE SWEDEN's market capitalization is EUR 144.71M.
What is SURGICAL SCIENCE SWEDEN's P/E ratio?
SURGICAL SCIENCE SWEDEN's price-to-earnings (P/E) ratio is 31.5.
What does SURGICAL SCIENCE SWEDEN do?
Surgical Science Sweden AB (publ) develops and markets virtual reality simulators and customized training solutions for evidence-based medical training in Europe, North and South America, Asia, and internationally. The company offers Angio Mentor simulator for endovascular training;